Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 0.93 below Jasper Therapeutics Inc 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 113 other companies have achieved higher Quick Ratio than Jasper Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1267 to 1868.

Explain Quick Ratio?
How much Cash & cash equivalents JSPR�s has?
What are JSPR�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

JSPR Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-61.73 %	-27.06 %	-21.99 %	68.88 %	103.62 %
Y / Y Cash & cash equivalent Change	-81.49 %	-71.02 %	-59.95 %	-44.98 %	-63.01 %
Quick Ratio MRQ	0.93	1.57	2.41	2.42	1.93
JSPR's Total Ranking	# 1868	# 1267	# 736	# 972	#
Seq. Current Liabilities Change	-12.79 %	-24.32 %	-43.51 %	2.64 %	66.21 %
Seq. Cash & cash equivalent Change	-48.29 %	-50.7 %	-43.63 %	28.83 %	-19.04 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 114
Healthcare Sector	# 640
Overall Market	# 1868

Quick Ratio Statistics
High	Average	Low
16.4	6.33	0.03
(Mar 31 2023)		(Jun 30 2021)

Financial Statements
Jasper Therapeutics Inc 's Current Liabilities	$ 8 Millions	Visit JSPR's Balance sheet
Jasper Therapeutics Inc 's Cash & cash equivalent	$ 7 Millions	Visit JSPR's Balance sheet
Source of JSPR's Sales		Visit JSPR's Sales by Geography

Cumulative Jasper Therapeutics Inc 's Quick Ratio

JSPR's Quick Ratio for the trailling 12 Months

JSPR Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-17.78 %	24.6 %	40.88 %	73.74 %	54.31 %
Y / Y Cash & cash equivalent TTM Growth	-59.97 %	-58.33 %	-56.89 %	-47.9 %	-39.32 %
Quick Ratio TTM	2.03	2.13	2.55	3.05	4.17
Total Ranking TTM	# 3881	# 3004	# 3160	# 2566	#
Seq. Current Liabilities TTM Growth	-20.27 %	-5.08 %	-4.85 %	14.18 %	20.82 %
Seq. Cash & cash equivalent TTM Growth	-24.16 %	-20.64 %	-20.37 %	-16.48 %	-21.05 %

Quick ratio ranking by company, industry and sector >> Back to JSPR Financial Strength Comparisons >> Go to Compare JSPR Quick Ratio to its Competitors

News about Jasper Therapeutics Inc Quick Ratio

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock, Aims to Enhance Treatment Approaches for Mast-Cell Driven Diseases

Jasper Therapeutics to Raise $50 Million in Common Stock Offering for Advancement of Mast-Cell Driven Disease Treatments
REDWOOD CITY, Calif., Feb. 06, 2024 - Jasper Therapeutics, a clinical-stage biotechnology company dedicated to developing innovative antibody therapies, has recently disclosed its plans to invest the considerable sum of $50 million in advancing its preclinical and clinical development programs. The funds will primarily be directed towards furthering the research and development of briquilimab, an antibody therapy designed to target c-Kit (CD117) and combat chronic spontaneous urticaria (CSU) and Chronic Inducible Urticaria (CIndU), both mast-cell driven diseases. Jasper Therapeutics also aims to explore the potential application of this therapy in addressing lower to intermediate risk myelodysplastic syndromes (MDS) and developing novel stem cell transplant conditioning regimes.
In order to accomplish this ambitious endeavor, Jasper Therapeutics has decided to undertake an underwritten offering of its common stock. The company plans to offer 3,900,000 shares of its common stock at a price of $12.95 per share, thus raising a total of approximately $50 million in gross proceeds. These figures, however, do not take into account any underwriting discounts, commissions, or offering expenses. It is important to note that all of the shares of common stock will be offered exclusively by Jasper.

On the trailing twelve months basis In spite of the year on year decrease in JSPR's Current Liabilities to $7.85 millions, cumulative Quick Ratio to 2.03 below the JSPR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 140 other companies have achieved higher Quick Ratio than Jasper Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3004 to 3881.

Explain Quick Ratio?
How much Cash & cash equivalents JSPR�s has?
What are JSPR�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 141
Healthcare Sector	# 884
Within the Market	# 3881

trailing twelve months Quick Ratio Statistics
High	Average	Low
12.41	7.44	1.98
(Mar 31 2024)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Tarsus Pharmaceuticals Inc	2.56	$ 449.690 Millions	$ 175.753 Millions
Meiragtx Holdings Plc	2.46	$ 143.166 Millions	$ 58.096 Millions
Kodiak Sciences Inc	2.39	$ 125.903 Millions	$ 52.770 Millions
Exelixis Inc	2.32	$ 839.385 Millions	$ 361.927 Millions
Precision Biosciences Inc	2.19	$ 87.549 Millions	$ 39.886 Millions
Novavax inc	2.18	$ 719.340 Millions	$ 330.574 Millions
Regenxbio Inc	2.11	$ 174.530 Millions	$ 82.621 Millions
Biocardia Inc	2.00	$ 4.117 Millions	$ 2.055 Millions
Kymera Therapeutics Inc	1.75	$ 124.477 Millions	$ 71.326 Millions
Biocryst Pharmaceuticals Inc	1.69	$ 353.279 Millions	$ 208.846 Millions
Coherus Oncology inc	1.69	$ 127.683 Millions	$ 75.510 Millions
Bio techne Corp	1.62	$ 264.712 Millions	$ 163.700 Millions
Atara Biotherapeutics Inc	1.45	$ 9.900 Millions	$ 6.847 Millions
Twist Bioscience Corporation	1.39	$ 166.839 Millions	$ 120.255 Millions
Neumora Therapeutics Inc	1.34	$ 116.834 Millions	$ 87.478 Millions
Calidi Biotherapeutics Inc	1.33	$ 4.290 Millions	$ 3.237 Millions
Passage Bio Inc	1.17	$ 24.155 Millions	$ 20.719 Millions
Mink Therapeutics Inc	1.16	$ 8.807 Millions	$ 7.569 Millions
Amgen Inc	1.07	$ 27,404.000 Millions	$ 25,502.000 Millions
Aligos Therapeutics Inc	1.07	$ 30.381 Millions	$ 28.343 Millions
Vaxart Inc	1.05	$ 77.058 Millions	$ 73.108 Millions
Iovance Biotherapeutics inc	1.04	$ 110.768 Millions	$ 106.848 Millions
Liminatus Pharma Inc	0.99	$ 3.017 Millions	$ 3.040 Millions
Elutia Inc	0.95	$ 19.896 Millions	$ 21.045 Millions
Jasper Therapeutics Inc	0.93	$ 7.314 Millions	$ 7.845 Millions
Protalix Biotherapeutics inc	0.90	$ 28.140 Millions	$ 31.391 Millions
Vivosim Labs Inc	0.88	$ 1.670 Millions	$ 1.893 Millions
Senti Biosciences Holdings Inc	0.83	$ 13.124 Millions	$ 15.765 Millions
Pelthos Therapeutics Inc	0.78	$ 24.776 Millions	$ 31.959 Millions
Ocugen Inc	0.75	$ 100.051 Millions	$ 133.080 Millions

Date modified: 2026-09-08T15:11:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.